PRONIA
Personalised Prognostic Tools for Early Psychosis Management
| Coordinatore | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.pronia.eu |
| Totale costo | 9˙242˙843 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2018-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | coordinator | 863˙015.00 |
| 2 |
DYNAMIC EVOLUTION GMBH
Organization address
address: LICHTENBERGSTRASSE 8 contact info |
DE (GARCHING) | participant | 833˙220.00 |
| 3 |
THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
UK (BIRMINGHAM) | participant | 689˙755.00 |
| 4 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 681˙550.00 |
| 5 |
UNIVERSITAET BASEL
Organization address
address: Petersplatz 1 contact info |
CH (BASEL) | participant | 673˙298.00 |
| 6 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | participant | 650˙340.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI UDINE
Organization address
address: VIA PALLADIO 8 contact info |
IT (UDINE) | participant | 641˙953.00 |
| 8 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 400˙000.00 |
| 9 |
General Electric Deutschland Holding GmbH
Organization address
address: Martin-Behaim str. 10 contact info |
DE (Neu-Isenburg) | participant | 293˙279.00 |
| 10 |
GE HEALTHCARE GMBH - GEHC
Organization address
address: BEETHOVENSTRASSE 239 contact info |
DE (SOLINGEN) | participant | 273˙590.00 |
| 11 |
UNIVERSITY OF MELBOURNE
Organization address
address: PARKVILLEOFFICE OF THE VICE CHANCELLOR contact info |
AU (MELBOURNE) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Affective and non-affective psychoses have a major negative impact on human society. They account for 6.3% of the global burden of disease and cost €207 billion per year in Europe alone, making them the most expensive brain-related disorders and even more expensive than cardiovascular diseases. This socioeconomic burden is largely caused by two core disease features: onset in adolescence and early adulthood and long-term disabling disease courses. Both factors lead to enduring social and vocational exclusion and contribute to 8-20 times higher suicide rates in affected patients. Reliable and accessible prognostic tools will alleviate this burden by enabling individualised risk prediction, thus facilitating the targeted prevention of psychoses. Thus, we will first use routine brain imaging and complementary data to optimise our candidate biomarkers for the prediction and staging of psychoses and generate a prognostic system that generalises well across mental health services. Secondly, we will implement new multi-modal risk quantification tools to predict mental health-related disability in young help-seekers. The fusion of these tools with clinical knowledge will produce cybernetic prognostic services that accurately identify help-seekers at the highest risk of psychosis, poor functioning and suicide-related mortality. During this project we will secure our intellectual property rights and transform into a European company to commercially exploit these prognostic services through internet-based telemedicine applications. This will provide psychosis risk profiling tools to diverse target groups in the healthcare markets, including care-givers, the pharmaceutical industry and research institutions. By disseminating objective risk quantification, these products will provide firm diagnostic grounds for preventive therapy, improving outcomes and reducing costs. Thus, they will offer a unique selling proposition to the mental health sectors in Europe and beyond.'